Highlights Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-11 pm EST			5-day change	1st Jan Change
7.380 ^USD	+9.66%		+77.83%	+235.45%

Dec. 09	Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants	RE
Dec. 08	Immix Biopharma Prices $100 Million Offering	MT

Highlights

Immix Biopharma prices offering of 19.1 million shares at $5.10 per share	Dec. 07	RE
Immix Biopharma, Inc. Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-In-Class Therapy for Relapsed/Refractory AL Amyloidosis	Dec. 07	CI
Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	Nov. 07	CI
Immix Biopharma, Inc. Announces 50% Enrollment Milestone Surpassed in Its Ongoing Relapsed/Refractory AL Amyloidosis Clinical Trial, NEXICART-2	Sep. 18	CI
Immix Biopharma, Inc. Appoints Nancy Chang, Ph.D. as A Member of the Board, Effective September 8, 2025	Sep. 08	CI
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	Aug. 08	CI
Immix Biopharma, Inc. Announces Other Serious Diseases Strategy	Aug. 06	CI
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion	Jul. 11	CI
Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2	May. 23	CI
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-In-Class Therapy for Relapsed/Refractory AL Amyloidosis	May. 22	CI
Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 08	CI
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 25	CI
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis	Feb. 10	CI
Immix Biopharma Says Patients Dosed in AL Amyloidosis Trial Safety Run-in Successfully Complete Safety Evaluation	Jan. 07	MT
Immix Biopharma, Inc. Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T	Jan. 07	CI
Sector Update: Health Care Stocks Decline Late Afternoon	Dec. 19	MT
Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis	Dec. 19	MT
Immix Biopharma Announces Positive U.S. Clinical Data from First Four Patients in Nexicart-2 U.S. Trial of Sterically-Optimized Car-T Nxc-201 in Relapsed/Refractory Light Chain (Al) Amyloidosis	Dec. 19	CI
Immix Biopharma, Inc. Announces Journal of Clinical Oncology Publishes NEXICART-2 Clinical Results in Relapsed/Refractory AL Amyloidosis	Dec. 16	CI
Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower	Dec. 10	MT
Immix Biopharma, Inc. Announces New Nxc-201 Nexicart-1 Clinical Data in Relapsed/Refractory Al Amyloidosis Patients At Ash 2024	Dec. 10	CI
Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 12	CI
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2	24-10-02	CI
Sector Update: Health Care Stocks Ease in Afternoon Trading	24-08-28	MT
Immix Biopharma, Inc. Announces the Addition of Three Additional Clinical Trial Sites for Its U.S. Relapsed/Refractory Al Amyloidosis Clinical Trial NEXICART-2	24-08-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Biotechnology & Medical Research

Highlights

Filters